All In Biotech

BLA 020725 · Abbvie

Creon

Pancrelipase (Amylase, Lipase, Protease) · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Apr 30, 2009

Approved uses

4

Original approval plus efficacy supplements

Registered trials

n/a

n/a Phase 3, n/a recruiting

FAERS reports

38,797

28,976 serious, 3,888 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 28, 2024.

CREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • CREON · PANCRELIPASE (AMYLASE 15,000USP UNITS; LIPASE 3,000USP UNITS; PROTEASE) 9,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • CREON · PANCRELIPASE (AMYLASE 60,000USP UNITS; LIPASE 12,000USP UNITS; PROTEASE) 38,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • CREON · PANCRELIPASE (AMYLASE 180,000USP UNITS; LIPASE 36,000USP UNITS; PROTEASE) 114,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • CREON · PANCRELIPASE (AMYLASE 120,000USP UNITS; LIPASE 24,000USP UNITS; PROTEASE) 76,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • CREON · PANCRELIPASE (AMYLASE 30,000USP UNITS; LIPASE 6,000USP UNITS; PROTEASE) 19,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.

All n/a trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea3,834
  • death2,040
  • nausea1,890
  • weight decreased1,856
  • fatigue1,660
  • abdominal pain1,572
  • vomiting1,475
  • pain1,338
  • abdominal pain upper1,311
  • pancreatic carcinoma1,295
  • infective pulmonary exacerbation of cystic fibrosis1,238
  • drug ineffective1,209

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004105
200594
200699
200786
2008127
2009191
2010290
2011380
2012498
2013686
2014958
20151,365
20161,772
20171,795
20182,451
20193,620
20203,401
20212,446
20222,749
20232,591
20243,627
20255,350
20264,115

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Sep 15, 2014 · Class II · Terminated

    Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Creon (Lipase/Protease/Amylase)

2024 spending

$1.49B

Beneficiaries

185,261

775,061 claims

Per beneficiary

$8,061

$8.76 per unit

View as table
YearSpending
2020$960,235,542
2021$1,111,601,793
2022$1,310,801,528
2023$1,466,866,603
2024$1,493,447,100

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.